RU2006108550A - Фармацевтические композиции и способы, включающие комбинации 2-алкилиденовых производных 9-нор-витамина d и бисфосфоната - Google Patents

Фармацевтические композиции и способы, включающие комбинации 2-алкилиденовых производных 9-нор-витамина d и бисфосфоната Download PDF

Info

Publication number
RU2006108550A
RU2006108550A RU2006108550/15A RU2006108550A RU2006108550A RU 2006108550 A RU2006108550 A RU 2006108550A RU 2006108550/15 A RU2006108550/15 A RU 2006108550/15A RU 2006108550 A RU2006108550 A RU 2006108550A RU 2006108550 A RU2006108550 A RU 2006108550A
Authority
RU
Russia
Prior art keywords
bisphosphonate
dihydroxyvitamin
methylene
osteoporosis
alendronate
Prior art date
Application number
RU2006108550/15A
Other languages
English (en)
Other versions
RU2326695C2 (ru
Inventor
Эндрю Джордж ЛИ (US)
Эндрю Джордж ЛИ
Original Assignee
Пфайзер Продактс Инк. (Us)
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. (Us), Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк. (Us)
Publication of RU2006108550A publication Critical patent/RU2006108550A/ru
Application granted granted Critical
Publication of RU2326695C2 publication Critical patent/RU2326695C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (15)

1. Фармацевтическая композиция, включающая соединение 2-метилен-19-нор-20(S)-1α,25-дигидроксивитамин D3 и бисфосфонат.
2. Композиция по п.1, в которой бисфосфонат выбран из тилудроната, алендроната, золедроната, ибандроната, ризедроната, этидроната, клодроната или памидроната.
3. Композиция по п.2, в которой бисфосфонат представляет собой алендронат.
4. Композиция по п.2, в которой бисфосфонат представляет собой ризедронат.
5. Способ лечения старческого остеопороза, постклимактерического остеопороза, переломов костей, костного трансплантата, рака груди, рака простаты, ожирения, остеопении, мужского остеопороза, слабости, поражений мышц или саркопении, включающий введение больному, нуждающемуся в этом, терапевтически эффективного количества 2-метилен-19-нор-20(S)-1α,25-дигидроксивитамина D3 и терапевтически эффективного количества бисфосфоната.
6. Способ по п.5, в котором 2-метилен-19-нор-20(S)-1α,25-дигидроксивитамин D3 и бисфосфонат вводят перорально.
7. Способ по п.5, в котором 2-метилен-19-нор-20(S)-1α,25-дигидроксивитамин D3 вводят парентерально.
8. Способ по п.5, в котором 2-метилен-19-нор-20(S)-1α,25-дигидроксивитамин D3 вводят трансдермально.
9. Способ по п.5, в котором 2-метилен-19-нор-20(S)-1α,25-дигидроксивитамин D3 и бисфосфонат вводят по существу одновременно.
10. Способ по п.5, которым лечат постклимактерический остеопороз.
11. Способ лечения старческого остеопороза, постклимактерического остеопороза, перелома костей, костного трансплантата, рака груди, рака простаты, ожирения, остеопении, мужского остеопороза, слабости, поражений мышц или саркопении, включающий введение больному, нуждающемуся в этом лечении, терапевтически эффективного количества 2-метилен-19-нор-20(S)-1α,25-дигидроксивитамина D3 и терапевтически эффективного количества бисфосфоната, выбранного из тилудроната, алендроната, золедроната, ибандроната, ризедроната, этидроната, клодроната или памидроната.
12. Способ по п.11, в котором бисфосфонат представляет собой алендронат.
13. Способ по п.12, которым лечат постклимактерический остеопороз.
14. Способ по п.11, в котором бисфосфонат представляет собой ризендронат.
15. Способ по п.14, которым лечат постклимактерический остеопороз.
RU2006108550/15A 2003-09-19 2004-09-06 Фармацевтические композиции и способы, включающие комбинации 2-алкилиденовых производных 9-нор-витамина d и бисфосфоната RU2326695C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50400803P 2003-09-19 2003-09-19
US60/504,008 2003-09-19

Publications (2)

Publication Number Publication Date
RU2006108550A true RU2006108550A (ru) 2007-09-27
RU2326695C2 RU2326695C2 (ru) 2008-06-20

Family

ID=34375430

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006108550/15A RU2326695C2 (ru) 2003-09-19 2004-09-06 Фармацевтические композиции и способы, включающие комбинации 2-алкилиденовых производных 9-нор-витамина d и бисфосфоната

Country Status (16)

Country Link
US (1) US20050065117A1 (ru)
EP (1) EP1667691A1 (ru)
JP (1) JP2007505886A (ru)
KR (1) KR20060058134A (ru)
CN (1) CN1852719A (ru)
AU (1) AU2004273672A1 (ru)
BR (1) BRPI0414565A (ru)
CA (1) CA2539359A1 (ru)
IL (1) IL174216A0 (ru)
MX (1) MXPA06003063A (ru)
NO (1) NO20061245L (ru)
NZ (1) NZ545804A (ru)
RU (1) RU2326695C2 (ru)
TW (1) TW200524617A (ru)
WO (1) WO2005027921A1 (ru)
ZA (1) ZA200602270B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009116888A1 (ru) * 2008-03-18 2009-09-24 Dikovskiy Aleksander Vladimiro Фармацевтическая композиция для профилактики и лечения резорбции костной ткани различной этиологии

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7122533B2 (en) * 1999-11-29 2006-10-17 The United States Of America As Represented By The Department Of Health And Human Services Cosalane compounds and methods for their use
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
WO2006061683A1 (en) * 2004-12-09 2006-06-15 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta
EP1798236A1 (en) * 2005-12-13 2007-06-20 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Process for the preparation of 3-pyridyl-1-hydroxyethylidene-1,1- biphosphonic acid and hydrated forms thereof
EP2007397B1 (en) * 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
US20100144679A1 (en) * 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
KR100844256B1 (ko) 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
US8999383B2 (en) * 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
TR200900880A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
TR200900878A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
SI2459176T1 (en) 2009-07-31 2018-01-31 Gruenenthal Gmbh Crystallization process and bioavailability
CN105920023A (zh) 2009-09-01 2016-09-07 杜克大学 双膦酸类组合物及其治疗心力衰竭的方法
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
EP2780021A4 (en) 2011-11-16 2015-08-05 Univ Duke BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING AND / OR REDUCING HEART FAILURE
US9012432B2 (en) * 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
US8859530B2 (en) 2013-03-08 2014-10-14 Voltarra Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
IT201700031017A1 (it) * 2017-03-21 2018-09-21 Bioenx S R L Composizioni utili per il trattamento dell'alopecia androgenica comprendenti acido etidronico
EP3648797A1 (en) 2017-07-05 2020-05-13 EPOS-Iasis Research and Development, Ltd Multifunctional conjugates
CN107550919A (zh) * 2017-09-04 2018-01-09 杭州旦承医药科技有限公司 唑来膦酸的用途及粉雾剂和制备方法
CN107441101A (zh) * 2017-09-04 2017-12-08 杭州旦承医药科技有限公司 伊班膦酸钠的用途及粉雾剂和制备方法
MX2021014028A (es) * 2019-05-17 2022-02-21 Univ Pennsylvania Métodos y composiciones para tratar obesidad y/o trastornos de la piel.
WO2023177283A1 (en) * 2022-03-14 2023-09-21 Erasmus University Medical Center Rotterdam A combination therapy for bone loss and/or muscle loss.

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
US4134969A (en) * 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
IT1194748B (it) * 1981-02-12 1988-09-28 Gentili Ist Spa Composizioni farmaceutiche per il trattamento di osteopatie
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE10199052I1 (de) * 1986-11-21 2002-01-10 Novartis Ag Neue substituierte Alkandiphosphonsaeuren
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
FR2629716B1 (fr) * 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
US6096342A (en) * 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
JP2898882B2 (ja) * 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
TW257765B (ru) * 1993-08-25 1995-09-21 Merck & Co Inc
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
NZ503946A (en) * 1997-06-11 2003-02-28 Procter & Gamble Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
SG109478A1 (en) * 1997-07-22 2005-03-30 Merck & Co Inc Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
GB9907908D0 (en) * 1999-04-07 1999-06-02 Bataille Regis Organic compounds
DE19935771A1 (de) * 1999-07-23 2001-02-01 Schering Ag Neue Vitamin D-Derivate mit cyclischen Substrukturen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
NZ528659A (en) * 2001-04-03 2005-02-25 Royal Alexandra Hosp Children A drug for use in bone grafting
JP2004528340A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト ビスホスホネートの医薬的使用
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009116888A1 (ru) * 2008-03-18 2009-09-24 Dikovskiy Aleksander Vladimiro Фармацевтическая композиция для профилактики и лечения резорбции костной ткани различной этиологии

Also Published As

Publication number Publication date
US20050065117A1 (en) 2005-03-24
BRPI0414565A (pt) 2006-11-07
EP1667691A1 (en) 2006-06-14
NO20061245L (no) 2006-05-31
WO2005027921A1 (en) 2005-03-31
MXPA06003063A (es) 2006-05-31
NZ545804A (en) 2009-09-25
KR20060058134A (ko) 2006-05-29
IL174216A0 (en) 2006-08-01
ZA200602270B (en) 2007-09-26
RU2326695C2 (ru) 2008-06-20
JP2007505886A (ja) 2007-03-15
CN1852719A (zh) 2006-10-25
CA2539359A1 (en) 2005-03-31
TW200524617A (en) 2005-08-01
AU2004273672A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
RU2006108550A (ru) Фармацевтические композиции и способы, включающие комбинации 2-алкилиденовых производных 9-нор-витамина d и бисфосфоната
RU2006136790A (ru) 8-(2-гидроксифенокси)октилдиетаноламин и его соли для доставки активных агентов
CY1106482T1 (el) Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
JP2002529490A5 (ru)
Fleisch Bisphosphonates: mechanisms of action and clinical use in osteoporosis-an update
CA2438848A1 (en) Compositions for delivering bisphosphonates
RU2006140888A (ru) Лекарственные формы на основе бисфосфонатов
TW200744673A (en) Improved ibandronate formulations
JP2004528303A5 (ru)
DE69331326T2 (de) Prostaglandin-analoga zur behandlung von osteoporose
RU96121563A (ru) Использование бисфосфонатов для ингибирования резорбции кости, возникающей вследствие имплантации ортопедических протезов
GB0029111D0 (en) Organic compounds
IL104109A (en) Pharmaceutical compositions containing aldenorate for treating periodontal diseases
EA200801261A1 (ru) Фармацевтические композиции на основе галлия и способы
JP2005530819A5 (ru)
RU2006110736A (ru) Комбинация, содержащая n-(3-метокси-5-метилпиразин-2-ил)-2-(1, 3, 4-оксадиазол-2-ил)пиридин-3-сульфонамид и lhrh- аналог и/или бифосфонат
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
DE69837450D1 (de) Alendronate zur Behandlung von Osteoporose
WO2004058235A3 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
Green Anti-tumor potential of bisphosphonates
DE60212621D1 (de) Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis
KR20020027562A (ko) 골절 치료용 약제
KR970705400A (ko) 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)
RU2004122433A (ru) Способ лечения костных нарушений
Lazar et al. Bisphosphonates in bone diseases treatment

Legal Events

Date Code Title Description
PC4A Invention patent assignment

Effective date: 20090119

MM4A The patent is invalid due to non-payment of fees

Effective date: 20090907